| Bristol-Myers Squibb SA - REVLIMID 7.5 mg, Hartkapseln | | 57712 | | 09 | | REVLIMID 7.5 mg | | Hartkapseln | | L04AX04 | | Lenalidomide | | 28.06.2016 | | |
| | Composition | | lenalidomidum 7.5 mg, lactosum 144.5 mg, cellulosum microcristallinum, carmellosum natricum conexum corresp. natrium 0.4 mg, magnesii stearas, Kapselhülle: gelatina, E 171, E 172 (flavum), Drucktinte: lacca, propylenglycolum, E 172 (nigrum), kalii hydroxidum, pro capsula. | | Packungsbestandteile | | Capsules | | | | | Principe actif | Concentr. |
|---|
| Lenalidomidum | 7.5 mg |
| | BAG: Principe actif | Concentr. |
|---|
| Lenalidomidum | 7.5 mg |
| | | | Agents auxilliaires | Concentr. | informations additionels |
|---|
| | | | | | | | | | | | | | | | | | | color. | | | | color. | | Gelatina | | Kapselhülle | | | | | | | | Drucktinte | | | 144.5 mg | | | | | | | | | | | Propylenglycol | | |
| |
| | numéro d'emballage | Taille des présentations | PEF | PP | Cat. | LS | Hors commerce (MedRef) |
|---|
| 007 | 21 | 2420.94 | 2545.00 | A | LS | Non |
|
|
